Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) – Equities researchers at Zacks Small Cap lifted their FY2022 earnings per share estimates for shares of Oramed Pharmaceuticals in a note issued to investors on Monday, November 21st. Zacks Small Cap analyst M. Marin now anticipates that the biotechnology company will earn ($0.64) per share for the year, up from their prior forecast of ($0.72). The consensus estimate for Oramed Pharmaceuticals’ current full-year earnings is ($0.93) per share. Zacks Small Cap also issued estimates for Oramed Pharmaceuticals’ Q4 2022 earnings at $0.03 EPS.
Other equities research analysts have also recently issued research reports about the company. StockNews.com initiated coverage on Oramed Pharmaceuticals in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. Alliance Global Partners lowered their price target on Oramed Pharmaceuticals to $35.00 in a report on Wednesday, November 16th.
Oramed Pharmaceuticals Price Performance
Institutional Investors Weigh In On Oramed Pharmaceuticals
Large investors have recently bought and sold shares of the stock. Point72 Hong Kong Ltd grew its holdings in Oramed Pharmaceuticals by 113.5% during the 1st quarter. Point72 Hong Kong Ltd now owns 4,552 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 2,420 shares during the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Oramed Pharmaceuticals in the 2nd quarter worth $51,000. UBS Group AG raised its position in shares of Oramed Pharmaceuticals by 84.9% in the 3rd quarter. UBS Group AG now owns 8,415 shares of the biotechnology company’s stock worth $54,000 after buying an additional 3,864 shares during the period. Amalgamated Bank purchased a new position in shares of Oramed Pharmaceuticals in the 1st quarter worth $56,000. Finally, Laurion Capital Management LP purchased a new position in shares of Oramed Pharmaceuticals in the 2nd quarter worth $57,000. Institutional investors and hedge funds own 17.06% of the company’s stock.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
- Get a free copy of the StockNews.com research report on Oramed Pharmaceuticals (ORMP)
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.